Minerva Neurosciences Inc. (NERV)
Summary
NERV Chart
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
Minerva Neurosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Farallon Capital Farallon Capital Management LLC | 2.37M | $9.51M | $10.36M | $851,400 | 8.96% |
| DP Drew Phillips Fortitude Family Office LLC | 303 | $1,218 | $1,293.81 | $75.81 | 6.22% |
 Christopher C. Powers Farther Finance Advisors, LLC | 100 | $170 | $427 | $257 | 151.18% |
 James B. Tananbaum Foresite Capital Management VI LLC | 1.99M | $11.97M | $8.48M | -$3.49M | -29.13% |
Minerva Neurosciences Inc. (NERV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Minerva Neurosciences Inc. ever had a stock split?
Minerva Neurosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Remy Luthringer CEO | NASDAQ (CM) Exchange | 603380205 CUSIP |
| US Country | 7 Employees | - Last Dividend | 21 Jun 2022 Last Split | 1 Jul 2014 IPO Date |
Overview
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with central nervous system (CNS) diseases. Founded in 2007, the company is at the forefront of addressing some of the most challenging conditions affecting the CNS, with a particular focus on schizophrenia, Parkinson's disease, and other neurodegenerative disorders. Headquartered in Burlington, Massachusetts, Minerva Neurosciences has established a strategic partnership with Mitsubishi Tanabe Pharma Corporation, which has granted it the rights to develop, sell, and import its lead product, roluperidone, in all territories outside of Asia. This collaboration underscores the global potential and significance of Minerva's pipeline in addressing unmet medical needs in the neurosciences field.
Products and Services
Roluperidone (MIN-101)
Roluperidone, also known as MIN-101, stands as Minerva Neurosciences' flagship product candidate. It is currently under development for addressing the negative symptoms experienced by patients with schizophrenia. Negative symptoms can include aspects like social withdrawal, lack of motivation, and reduced emotional expressiveness, which significantly impair quality of life. Minerva has progressed to the stage of submitting a New Drug Application (NDA) for roluperidone, marking a pivotal step towards its potential approval and commercial use. The global license agreement with Mitsubishi Tanabe Pharma Corporation for the development, sales, and importation of roluperidone (excluding Asia) highlights its significance and potential impact on psychopharmacology.
MIN-301
MIN-301 is another prominent contender in Minerva's product pipeline, characterized as a soluble recombinant form of the neuregulin-1b1 protein. This innovative therapeutic approach is aimed at treating Parkinson's disease and other neurodegenerative disorders, potentially offering a new avenue of hope for patients afflicted by these conditions. By targeting the underlying mechanisms that contribute to neurodegeneration, MIN-301 represents a novel approach that could complement or enhance existing treatments for Parkinson’s disease and similar neurodegenerative disorders.
